文献速递神经肿瘤

复发胶质母细胞瘤与治疗后改变:18F-FET PET的诊断准确性

Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
PubMed 文献 · Neuro Oncol · 2019-01-01

本研究回顾性分析146例胶质母细胞瘤患者的168次18F-FET PET扫描,评估标准化放疗后6个月、MRI怀疑复发时20分钟18F-FET PET的诊断准确性及预后价值。ROC分析确定TBRmax阈值2.0、TBRmean阈值1.8、BTV阈值0.55 cm³,TBRmax表现最佳(敏感性99%,特异性94%;P<0.0001)。BTV增加与总生存期缩短相关(P<0.0001)。

要点

  • 20分钟18F-FET PET可有效鉴别放疗后6个月的复发胶质母细胞瘤与治疗后改变。
  • TBRmax阈值2.0诊断性能最佳,敏感性99%、特异性94%。
  • BTV增加与总生存期缩短独立相关,可用于预后评估。

核心结论

  • 20分钟18F-FET PET扫描是区分标准化放疗后6个月复发胶质母细胞瘤与治疗后改变的有力工具,并可预测总生存期。

研究设计与样本

  • 回顾性研究,纳入146例胶质母细胞瘤患者的168次18F-FET PET扫描。
  • 排除对贝伐珠单抗MRI应答、或在18F-FET PET后接受再放疗或免疫治疗的患者。
  • 记录TBRmax、TBRmean和BTV,并通过组织病理学或临床/影像学随访验证。
  • 采用ROC分析确定18F-FET参数阈值,采用Cox比例风险模型研究预后因素。

主要发现

  • 104次18F-FET PET扫描后行手术,64次行临床/影像学监测,共识别152例胶质母细胞瘤复发和16例治疗后改变。
  • ROC分析得出鉴别复发胶质母细胞瘤与治疗后改变的阈值:TBRmax为2.0,TBRmean为1.8,BTV为0.55 cm³。
  • TBRmax表现最佳(敏感性99%,特异性94%;P<0.0001),其次为BTV(敏感性98%,特异性94%;P<0.0001)。
  • 使用上述阈值,166次18F-FET PET扫描被正确分类。
  • BTV增加与总生存期缩短相关(P<0.0001)。

关键数值与推荐

  • TBRmax阈值2.0:鉴别复发胶质母细胞瘤与治疗后改变,敏感性99%,特异性94%,P<0.0001。
  • TBRmean阈值1.8:用于鉴别诊断。
  • BTV阈值0.55 cm³:鉴别复发胶质母细胞瘤与治疗后改变,敏感性98%,特异性94%,P<0.0001。

临床怎么用

  • 对标准化放疗后6个月MRI怀疑复发的胶质母细胞瘤患者,可考虑行20分钟18F-FET PET扫描以鉴别复发与治疗后改变。
  • 可采用TBRmax≥2.0、TBRmean≥1.8或BTV≥0.55 cm³作为辅助诊断阈值。
  • BTV增大提示总生存期较短,可用于预后分层。

局限性

  • 本研究为回顾性设计。
  • 排除对贝伐珠单抗MRI应答及后续接受再放疗或免疫治疗的患者,可能限制结论外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diagnostic accuracy in previous studies of O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in patients with suspected recurrent glioma may be influenced by prolonged dynamic PET acquisitions, heterogeneous populations, different non-standard-of-care therapies, and PET scans performed at different time points post radiotherapy. We investigated the diagnostic accuracy of a 20-minute 18F-FET PET scan in MRI-suspected recurrent glioblastoma 6 months after standard radiotherapy and its ability to prognosticate overall survival (OS). METHODS: In total, 146 glioblastoma patients with 168 18F-FET PET scans were reviewed retrospectively. Patients with MRI responses to bevacizumab or undergoing re-irradiation or immunotherapy after 18F-FET PET were excluded. Maximum and mean tumor-to-background ratios (TBRmax, TBRmean) and biological tumor volume (BTV) were recorded and verified by histopathology or clinical/radiological follow-up. Thresholds of 18F-FET parameters were determined by receiver operating characteristic (ROC) analysis. Prognostic factors were investigated in Cox proportional hazards models. RESULTS: Surgery was performed after 104 18F-FET PET scans, while clinical/radiological surveillance was used following 64, identifying 152 glioblastoma recurrences and 16 posttreatment changes. ROC analysis yielded thresholds of 2.0 for TBRmax, 1.8 for TBRmean, and 0.55 cm3 for BTV in differentiating recurrent glioblastoma from posttreatment changes with the best performance of TBRmax (sensitivity 99%, specificity 94%; P < 0.0001) followed by BTV (sensitivity 98%, specificity 94%; P < 0.0001). Using these thresholds, 166 18F-FET PET scans were correctly classified. Increasing BTV was associated with shorter OS (P < 0.0001). CONCLUSION: A 20-minute 18F-FET PET scan is a powerful tool to distinguish posttreatment changes from recurrent glioblastoma 6-month postradiotherapy, and predicts OS.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Bashir A, Mathilde Jacobsen S, Mølby Henriksen O, et al. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). Neuro Oncol. 2019. PMID: 31618420. doi:10.1093/neuonc/noz166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。